ArticleScience advances2025
Microfluidic-derived montmorillonite composite microparticles for oral codelivery of probiotic biofilm and postbiotics.
Article in Science advances, 2025. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 16 papers, 1 of them a synthesis that pooled it.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
16 citing papers in PubMed, 1 synthesis or guideline pooled it.
- Enabling Clinical Translation of Oral Probiotics Through Formulation Engineering and Scalable Manufacturing.Biotechnology journal · 2026Pooled it
- Harnessing microfluidics for microbiology: from bacteria-host interactions to emerging cancer therapies.Communications biology · 2026Review
- Multifunctional Zinc Glycyrrhizinate-Integrated Gel for Enhanced Probiotic Delivery and Alleviation of Acute and Spontaneous Colitis.Advanced science (Weinheim, Baden-Wurttemberg, Germany) · 2026Article
- Oral probiotic delivery-based therapeutic strategies for inflammatory bowel disease.Asian journal of pharmaceutical sciences · 2026Review
- Programmable microbial therapeutics: advances in engineered bacteria for targeted in vivo delivery and precision medicine.Journal of advanced research · 2026Review
- Polysaccharide-Based Encapsulation of Microbes for Enhanced Microbial Therapy.Polymer science & technology (Washington, D.C.) · 2026Review
- Alginate Microcapsules Incorporating Recombinant Lactococcus lactis-Montmorillonite Complexes Enhance Bacterial Survival and Restore Intestinal Homeostasis in ETEC-Challenged Mice.Probiotics and antimicrobial proteins · 2026Article
- Calcium montmorillonite clay: a clinically oriented narrative review of emerging perioperative and supportive applications.Annals of translational medicine · 2026Review
- Self-Adaptive Allantoin@ZIF8 Nanocomposite Hydrogel with Resveratrol Synergy for MRSA-Infected Wound Regeneration.Advanced science (Weinheim, Baden-Wurttemberg, Germany) · 2026Article
- CLDN3 inhibits rotavirus attachment by targeting residue 74 of VP7.PLoS pathogens · 2026Article
- Probiotics for ulcerative colitis: mechanisms, therapeutic advances, and emerging strategies.Frontiers in microbiology · 2026Review
- A review of biomaterials mediated probiotics delivery system in the field of inflammatory bowel disease treatment.Archives of microbiology · 2025Review
- Postbiotics in the food industry: applications, delivery systems, and future perspectives.Archives of microbiology · 2025Review
- Article
- Using Postbiotics from Functional Foods for Managing Colorectal Cancer: Mechanisms, Sources, Therapeutic Potential, and Clinical Perspectives.Microorganisms · 2025Review
- Design and Optimization of Chitosan/Montmorillonite Nanoparticle for Sustained Vancomycin Delivery in Peri-implantitis.Iranian journal of pharmaceutical research : IJPRArticle
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
3 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
Oral delivery of probiotics has shown promising effects in modulating the gut microbiota and treating ulcerative colitis (UC). However, the therapeutic efficacy is restricted by gastrointestinal assaults, poor mucosal adhesion, and single therapeutic modality. Here, we developed acid-resistant, gut-environment-responsive composite microparticles based on microfluidic electrospray for the oral codelivery of probiotic [
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.